186 related articles for article (PubMed ID: 30526127)
1. Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?
Lee S; Cohen DJ
Expert Opin Pharmacother; 2019 Feb; 20(3):357-366. PubMed ID: 30526127
[TBL] [Abstract][Full Text] [Related]
2. Basis for molecular diagnostics and immunotherapy for esophageal cancer.
Abdo J; Agrawal DK; Mittal SK
Expert Rev Anticancer Ther; 2017 Jan; 17(1):33-45. PubMed ID: 27838937
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Advances in the Treatment of Gastroesophageal Cancers.
Li JJ; Rogers JE; Yamashita K; Waters RE; Blum Murphy M; Ajani JA
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238666
[TBL] [Abstract][Full Text] [Related]
4. Emerging immunotherapy for the treatment of esophageal cancer.
Jackie Oh S; Han S; Lee W; Lockhart AC
Expert Opin Investig Drugs; 2016 Jun; 25(6):667-77. PubMed ID: 26950826
[TBL] [Abstract][Full Text] [Related]
5. Novel chemotherapeutics and other therapies for treating high-grade glioma.
Kang JH; Adamson C
Expert Opin Investig Drugs; 2015; 24(10):1361-79. PubMed ID: 26289791
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
Bockorny B; Pectasides E
Future Oncol; 2016 Aug; 12(15):1833-46. PubMed ID: 27166503
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
8. Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches.
Lonie JM; Barbour AP; Dolcetti R
Cancer Treat Rev; 2021 Jul; 98():102219. PubMed ID: 33993033
[TBL] [Abstract][Full Text] [Related]
9. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
10. Progress and challenges in gastroesophageal cancer.
Serra O; Smyth EC; Lordick F
Curr Probl Cancer; 2020 Dec; 44(6):100590. PubMed ID: 32451067
[TBL] [Abstract][Full Text] [Related]
11. Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives.
Sardaro A; Ferrari C; Carbonara R; Altini C; Lavelli V; Rubini G
Cancer Biother Radiopharm; 2021 Mar; 36(2):123-132. PubMed ID: 32551915
[No Abstract] [Full Text] [Related]
12. Recent advances in immune-based approaches for the treatment of esophagogastric cancer.
Weadick CS; Duffy AG; Kelly RJ
Expert Opin Emerg Drugs; 2022 Mar; 27(1):19-31. PubMed ID: 34937483
[TBL] [Abstract][Full Text] [Related]
13. Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer.
Mamdani H; Jalal SI
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-16. PubMed ID: 33770461
[TBL] [Abstract][Full Text] [Related]
14. Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer.
Bolm L; Käsmann L; Paysen A; Karapetis C; Rades D; Wellner UF; Keck T; Watson DI; Hummel R; Hussey DJ
Anticancer Res; 2018 Jun; 38(6):3231-3242. PubMed ID: 29848670
[TBL] [Abstract][Full Text] [Related]
15. Evolving treatments for advanced gastric cancer: appraisal of the survival trend.
Roberto M; Romiti A; Onesti CE; Zullo A; Falcone R; Marchetti P
Expert Rev Anticancer Ther; 2016 Jul; 16(7):717-29. PubMed ID: 27137418
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer.
Forde PM; Kelly RJ
J Thorac Oncol; 2013 Jun; 8(6):673-84. PubMed ID: 23591158
[TBL] [Abstract][Full Text] [Related]
17. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Kaur A; Dasanu CA
Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?
Dillman RO; Cornforth AN; Nistor G
Expert Opin Biol Ther; 2013 May; 13(5):643-56. PubMed ID: 23451922
[TBL] [Abstract][Full Text] [Related]
19. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
Flynn MJ; Larkin JMG
Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
